Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247532 | 0.94 | KCNH2 (0.73) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL11260878 | 0.94 | KCNH2 (0.73) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL3870090 | 0.92 | HTR1A (0.69) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL8045431 | 0.89 | KCNH2 (0.69) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL3197065 | 0.86 | CACNA1G (0.52) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL2386501 | 0.86 | GFER (0.54) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL11338189 | 0.86 | HTR1A (0.65) | HTR1AHTR7KCNH2CYP2D6DRD2 | |
| SCHEMBL3194779 | 0.85 | HTR7 (0.55) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL4515279 | 0.84 | KDM4E (0.58) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL11828902 | 0.84 | HTR1A (0.68) | HTR1AHTR7KCNH2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | claimed |
| US-8575185-B2 | Compositions, synthesis, and methods of utilizing quinazolinedione derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | HTR1A 66/4885HTR7 119/4885KCNH2 1015/4885 |
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | GRIN2D, GRIK5, GRIK4 | HTR1A 398/4885HTR7 236/4885KCNH2 1292/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HTR1A 15/4885HTR7 17/4885KCNH2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.